Trial Profile
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC 0123-0000-0338 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin 338 (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- 28 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Apr 2011 Actual initiation date (April 2011) added as reported by ClinicalTrials.gov.